Allurion Technologies, Inc. (NYSE:ALUR) Accelerates FDA Pathway; Balance Sheet Stabilization Ahead
Momentum centers on regulatory progress and capital restructuring while operational metrics show material stress; the near-term outlook hinges on FDA milestones and recent financing steps.







